BioWorld

Oct. 31, 2007

Amgen Spinout Relypsa Starts Business With $33M Series A

If the story of newly established Relypsa Inc., a company created to develop nonabsorbed polymeric drugs for renal and cardiovascular diseases, sounds more than a little familiar, that's probably because it is. (BioWorld Today) Read More

India's Glenmark in $350M Deal With Lilly For Pain Compound

Acceleron Series C Gets $31M For Bone, Muscle Growth Bids

Genoptix IPO Soars 56 percent; RXi Files For Independence

Neurobiological Offering Nets $56 Million For Viprinex Trials

Other News To Note

U.S. Patent Disclosures

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Feb. 6, 2025.

MJFF grant supports Bexorg’s translational biomarker work

BioWorld Science

Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...

REST emerges as biomarker in ALS, knockdown improves ALS symptoms

BioWorld Science

About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...

Serotonin receptor modulators for the treatment of OUD

BioWorld Science

Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...

KLF15 shows potential as marker, target for cholangiocarcinoma

BioWorld Science

Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...